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ABSTRACT 
ACETALDEHYDE DEHYDROGENASE 2 (ALDH2) ACTIVATION PROTECTS HEPATOCYTES 
FROM MITOCHONDRIAL DAMAGE AND DEATH CAUSED BY 4-HYDROXYNONENAL 
Keegan J. Baldauf 
August6,2012 
Alcoholic liver disease (ALD) ranks among the major causes of morbidity and mortality in 
the world and effects millions of patients each year. Progression of ALD is well characterized and 
is actually a spectrum of liver diseases, which progresses from steatosis, to inflammation and 
necrosis, to finally fibrosis and cirrhosis. However, the underlying mechanism(s) of ALD are not 
as well understood, and as a result there is no FDA-approved therapy to prevent or reverse the 
disease. With a better understanding of the mechanism(s) and risk factors that mediate the 
initiation and progression of ALD, a targeted therapy can be developed to treat or prevent it. The 
regenerative capacity of the liver is inhibited in fibrosis and cirrhosis. By enhancing the 
regenerative ability of the liver we may be able to reverse the effects of ALD. Indeed, recent in 
vivo studies by this group indicate that activating Aldehyde Dehydrogenase 2 (ALDH2) with Alda-
1 (a novel ALDH2 activator) or Ethanol (EtOH) protects against oxidative stress and damage to 
the liver, as result enhancing regeneration. Because ALDH2 can protect mitochondria from 
oxidative stress that results from partial hepatectomy, oxidative stress from other sources should 
be protected against as well. To test this hypothesis, primary hepatocytes were isolated from 
mice and plated on 96-well plates for analysis via Cellomics High Content Screening. Some mice 
were administered EtOH for 3 days prior to hepatocyte isolation or exposed to Alda-1 to activate 
ALDH2. Cells were exposed to 4-Hydroxynonenal (4-HNE; 0-1000 j.JM) for 0-24 H. Activation of 
ALDH2, by pretreatment with EtOH or Alda-1 preexposure, clearly protected isolated hepatocytes 
from 4-HNE toxicity. Mitochondrial membrane potential was significantly increased in cells with 
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activated ALDH2 and membrane permeability was decreased in these cells as well. These 
changes in hepatocyte viability indicate that activation of ALDH2 protects cells from oxidative 
stress. 
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INTRODUCTION 
Alcoholic liver disease (ALD) ranks among the major causes of morbidity and mortality in the 
world and affects millions of patients each year. 1 Progression of ALD is well characterized and is 
actually a spectrum of liver diseases, from steatosis, to inflammation and necrosis, to finally 
fibrosis and cirrhosis. 2 However, the underlying mechanism(s) of ALD are not as well 
understood, and as a result there is no FDA-approved therapy to prevent or reverse this disease. 
With a better understanding of the mechanism(s) and risk factors that mediate the initiation and 
progression of ALD, a targeted therapy can be developed to treat or prevent it. 
The liver has tremendous regenerative capacity; which distinguishes it from other vital organs 
(e.g., the brain, heart and lungs) which are not as readily able to replace functional tissue that has 
been lost. In experimental models, the liver was able to regenerate from partial hepatectomy 
(PHx) from 5 to 8 days in rodents. 3 Hepatocytes rarely proliferate in healthy adults but following 
70% PHx, hepatocytes divide once or twice before returning to a quiescent state. 4 The ability of 
the liver to regenerate is a process which requires interplay between several pathways 
(cytokines, growth factors and metabolic networks).5 Changes in anyone of these pathways can 
impair the ability of the liver to regenerate from injury. The regenerative capacity of the liver is 
inhibited in fibrosis and cirrhosis.6 Therefore, enhancing hepatic regeneration could be an 
effective strategy to prevent the progression of ALD. 
Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme that oxidizes acetaldehyde to 
acetic acid, which is the final step in EtOH oxidationY A polymorphism of ALDH2 (ALDH2*2) is 
a common variant with decreased activity. ALDH2*2 heterozygous individuals have significantly 
higher acetaldehyde levels after ingestion of EtOH.9 It is known that ALDH2 loss-of-function 
polymorph isms increase the relative risk of developing ALD.9 Given the known toxicity of 
acetaldehyde, this risk association with alcohol consumption is not necessarily 
surprising. However, the same polymorphism also increases the risk of development of other 
chronic liver diseases [e.g., HCC and NAFLD1Q,11,12]. These data suggest that other factors 
besides alcohol metabolism may contribute to the increased risk of the development of liver 
disease in patients with the ALDH2 polymorphism. 
In preliminary studies, our group has shown acute administration of ethanol activates ALDH2 
which enhances hepatic regeneration (Figure 1). Furthermore, treatment with Alda-1, an ALDH2 
activating compound, mimicked the effects of acute EtOH preexposure and treatment with 
Daidzin (ALDH2 inhibitor) prevented the EtOH effect. These results support the hypothesis that 
activation of ALDH2 enhances hepatic regeneration. Lipid peroxides are byproducts of PHx that 
cause mitochondrial damage which can lead to blunted regeneration. 13 It is hypothesized that 
pretreatment with EtOH activates ALDH2 and attenuates the increased lipid peroxidation seen 
following PHx in these studies. By elUCidating this mechanism we can develop new therapies 
based on targeting ALDH2 to enhance hepatic regeneration. 
To that end, we employed Cellomics Array Scan High Content Screening (HCS) to evaluate 
this protective effect against hepatotoxicity induced by lipid aldehydes in isolated hepatocytes. 
Cellomics HCS used a 96-well plate design to analyze cell parameters via fluorescent dyes and 
allows for both visualization and quantification of the fluorescence. O'Brien et al reported that 
using HCS they were able to predict hepatotoxicity sensitivity at 93% and specificity at 98% for 
known compounds. 14 These results showed a marked increase in sensitivity from other 
conventional cytotoxicity assays for human hepatotoxicity. The authors hypothesized most 
cytotoxicity assays measure one endpoint, whereas there are many mechanisms for toxicity. 
Cellomics HCS allows us to evaluate several parameters which include inner mitochondrial 
membrane potential, cell membrane permeability and nuclear size that can be indicative of 
hepatotoxicity. We employed this method to evaluate whether modifying ALDH2 activity would 
alter the above mentioned parameters. 
4-Hydroxynonenal (4-HNE) is a lipid aldehyde that is toxic to cells and studies have shown 
that it is implicated in the pathogenesis of an extensive list of diseases including alcoholic liver 
disease.15 The lipid aldehyde is derived from n-6 polyunsaturated fatty acids (PUFAs) (e.g., 
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linoleic acid, linolenic acid and arachidonic aCid).16 Metabolism of 4-HNE to 4-hydroxynon-2-
enoic acid (4HNA) is catalyzed by ALDH2; an enzyme which can also be inactivated by high 
concentrations of 4_HNE.17,18 The inner mitochondrial membrane (IMM) is composed of a high 
concentration of PUFAs which renders it susceptible to oxidative stress and the generation of 4-
HNE.19 By modulating the activity of ALDH2, thus altering metabolism of 4-HNE, we attempted to 
build on the effects seen in our whole animal model previously. 
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MATERIALS AND METHODS 
Animals and treatments 
Male C57BLl6J mice (6-8 weeks old) were purchased from Jackson Laboratory (Bar 
Harbor, ME). Mice were housed in a pathogen-free barrier facility accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care, and procedures were approved by 
the local Institutional Animal Care and Use Committee. Food and tap water were allowed ad 
libitum. 
In experiments designed to test the effects of EtOH on 4-HNE toxicity, 2 mice per group 
were administered EtOH (6 mg/kg i.g. diluted in water) or, an isocaloric/isovolumetric contol, 
Maltose-Dextrin (MD) for 3 days q.a.m. Hepatocytes from the mice were isolated 24 H after the 
last i.g. dosing and seeded on 96 well plates (10,000 cells/well) for analysis by Cellomics HCS 
(Fig. 2). The hepatocytes from each mouse were plated across 2 rows of the 96-well plate for 
analysis. This allows duplicate wells from each mouse at each concentration of 4-HNE. In 
experiments designed to test the protective effects of Alda-1 on 4-HNE exposure, hepatocytes 
were isolated from mice and seeded on 96-well plates at a density of 10,000 cells/well (Fig. 2). 
Each 96-well plate consisted of hepatocytes isolated from a single mouse for the Alda-1 
experiments. To analyze the inhibitory effect of Daidzin on Alda-1-mediated activation of ALDH2 
the plate design mirrored that of the Alda-1 experiments. 
Partial Hepatectomy 
Results in Figure 1 were from Ding et al (in publication) in which seventy percent partial 
hepatectomies were performed as described by Greene and Puder, with minor modifications.2o 
Briefly, anesthesia was initiated and maintained with isoflurane (2% with 2L1min O2 flow). A 
vertical midline incision was made in the skin of the abdomen from the xiphoid cartilage extending 
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to the midabdomen. The falciform ligament above the median lobe was cut just proximal to the 
superior vena cava. The left lateral and median lobes were ligated with 4-0 silk and cut away 
from the liver using microsurgery scissors. Mice were anesthetized with ketaminelxylazine 
(1000/15 mglkg, i.m.) at time of sacrifice. 
Histology 
The capacity of liver regeneration was assessed by proliferating-cell-nuclear-antigen 
(PCNA) staining in Ding et al (in publication). PCNA staining employed a monoclonal mouse anti-
PCNA clone PC10 (Dako, Glostrup, Denmark) and a peroxidase-linked secondary antibody and 
diaminobenzidine (ARK peroxidase for mouse primary antibodies, DAKO, Carpinteria, CA). Cell 
cycle progression (per 1,000 hepatocytes) was estimated via PCNA staining as described 
. I 21 prevIous y. 
Enzymatic assay for aldehyde dehydrogenases 
Liver samples for total ALDHs activity were homogenized in RIPA buffer [20 mM Tris/CI, 
pH 7.5,150 mM NaCI, 1 mM EDTA, 1 mM EGTA, 1% (w/v) Triton X-100], containing protease 
and phophatase inhibitor cocktails (Sigma, St. Louis, MO). Mitochondrial protein for the ALDH2 
activity assay was extracted from the liver, as described by Wiekowski et al. 22 This work was 
performed by Ding et al (in publication). 
Perfusion and hepatocyte isolation 
A vertical midline incision was made in the skin of the abdomen from the xiphoid cartilage 
extending to the midabdomen. The inferior vena cava (IVC) was exposed and a 20G catheter 
was inserted into the vein. Ethylene glycol tetraacetic acid (EGTA) solution was perfused through 
the liver at a rate of 5 mLlmin and the portal vein was cut to allow the perfusion fluid to exit the 
liver. Immediately following the cutting of the portal vein the chest cavity is opened and the 
suprahepatic IVC was clamped. EGTA solution was perfused through the liver (5 mLlmin) for 5 
minutes under a heat lamp. Following the EGTA solution, a collagenase solution containing 
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collagenase D will be perfused through the liver for 8 minutes under a heat lamp. All perfusates 
were kept at 40°C prior to perfusion through the liver. Following the perfusion with collagenase 
solution containing collagenase D, the liver was removed and minced in media on ice. The cells 
were filtered through a sterile BD Falcon nylon cell strainer (70 IJm) and placed in a 50 mL 
polypropylene conical tube. The tube was spun in a centrifuge at 400 rpm for 5 min at 4°C. The 
supernatant was removed and hepatocytes were resuspended in Hanks Balanced Salt Solution 
(HBSS) and Percoll Solution and spun at 400 rpm for 20 minutes at 4°C. The supernatant 
following this spin was removed prior to suspending the remaining hepatocytes in HBSS and 
spun again at 400 rpm for 5 minutes at 4°C 2 times. An aliquot was taken prior to the second 
spin and cell viability was assessed using Trypan blue staining of dead cells. Perfusions 
performed in which cell viability was less than 85% were not included in supplemental 
experimental steps. 
Cellomics Analysis 
Hepatocytes were seeded on a 96-well plate at 10,000 cells/well in 100 IJL of media and 
incubated at 3rC in 5% CO2 for 24 H to allow attachment of the cells to the plate. For the Alda-1 
experiments, hepatocytes were preincubated with Alda-1 (1.52 IJM) and/or Daidzin (60 IJM) for 1 
H prior to exposure to 4-HNE from 4 to 24 H. 4-HNE is a lipid aldehyde that is a major product of 
lipid peroxidation and is toxic to cells. 17 The concentration of Alda-1 used for the experiments 
was determined by performing a series of dose range finding studies. After the exposure period 
the media was removed and media containing dyes to assess cell function: Hoechst (nuclear 
area), TMRM (mitochondrial membrane potential), and TOTO-3 (plasma membrane permeability) 
were added. The plate was assessed via the Cellomics Array Scan HCS (Pittsburgh, PA). 
Statistical analyses 
Summary data are means ± SEM. One-way analysis of variance (ANOVA) ANOVA with 
Bonferroni's post-hoc test or the Mann-Whitney rank sum test was used for the determination of 
statistical significance among treatment groups, as appropriate. a, p < 0.05 compared to MD 




The first phase of our method development involved generating a protocol for hepatocyte 
isolation that yielded greater than 85% viability. The 85% viability threshold was established from 
previous literature on murine hepatocyte isolation.23,24 We chose to analyze hepatocytes that 
were incubated no longer than 48 H based on literature that noted altered hepatocyte function 
and morphology approximately 4 days after isolation.25,26,27 The hepatocytes were plated at a 
density of 10,000 cells/well in 96-well plates based on experiments performed in the laboratory 
employing the Cellomics HCS. 
Initial experiments performed with the Cellomics HCS used factory recommended 
fluorescent dye concentrations as follows: Hoechst (0.8 I-IM), TMRM (0.020 I-IM), TOTO-3 (1 I-IM) 
and Flou-4 (1 I-IM). It is imperative to have a well-defined nuclear area, because all Cellomics 
HCS acquisition data are determined from the presence of a nucleus. In our initial experiment the 
Cellomics HCS was unable to acquire nuclei because the concentration of Hoechst in the media 
was too low. This was a result of the hepatocytes' ability to export Hoechst by an ABC 
transporter.28 To counter the efflux of Hoechst we experimented with multiple concentrations of 
Hoechst dye and determined that a final concentration of 12.5 I-IM Hoechst would be used for all 
experiments discussed in the results. Additionally, we found that Flou-4 (excitation 475 nm and 
emission 515 nm) could not be evaluated because of the high background created from 
flavonoids (excitation 468 nm and emission 525 nm) present in the hepatocyte plasma 
membrane.29 Based on this information and the excitation and emission parameters from the 
other fluorescent dyes we elected to remove this dye from our analyses. 
The next step was to determine a test compound to evaluate if ALDH2 modulation could 
alter hepatocyte toxicity. 4-HNE has been associated with several hepatic diseases, is a product 
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of oxidative stress in the liver, and is a known inactivator of ALDH2. 30,31 Additionally, 4-HNE was 
an endpoint for the evaluation of Alda-1 which was used to enhance ALDH2 activity.32 Early 
experiments employed a 96-well plate design with a serial dilution (1 :2) of 4-HNE ranging from 1 
mM down to 1.9 IJM and control wells (0 IJM). This range allowed us to show a range from no 
effect (0 IJM) through total hepatocyte killing (500 IJM). 
Alda-1 is a small-molecule activator of ALDH2 which was developed in the Mochly-Rosen 
Laboratory.32 Based off of the methods from the Mochly-Rosen Laboratory, we selected a range 
of concentrations to pursue that encompassed all of the test concentrations previously used.32,33 
We determined that in our hands a concentration of 1.52 IJM Alda-1 was the most efficient 
concentration. As the concentration increased, we saw no additive effect on protection and an 
increasing amount of background fluorescence. 
Daidzin, which inactivates ALDH2, was also incubated with hepatocytes to determine if it 
would blunt Alda-1 protection or increase cell death at lower concentrations of 4-HNE. Daidzin 
had previously been used in experiments with Alda-1 and was found to have an overlapping 
binding site near the exit of the substrate tunnel. 33 After searching the literature we determined 
that a concentration of 60 IJM of Daidzin was appropriate for the purpose of the experiments.33,34 
Following the development of the techniques mentioned above we were able to perform 
our experiments. The isolation and initial incubation of hepatocytes was similar regardless of the 
method by which we activated ALDH2. EtOH pretreatment was performed prior to hepatocyte 
isolation and the addition of Alda-1 and Daidzin pretreatment was performed in vitro for the 
respective experiments. Addition of 4-HNE was identical regardless of pretreatment method. 
Analyses were performed using a protocol developed on the Cellomics HCS during the 
developmental phase. 
Increasing ALDH2 activity with Alda-1 protects hepatocytes 
Because Alda-1 is a known ALDH2 activating compound, increased ALDH2 activity 
should protect against exposure to higher concentrations of 4_HNE.32 Multiple concentrations of 
4-HNE were tested to evaluate hepatocyte function. 
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Mitochondrial membrane potential (TMRM fluorescence) was decreased in hepatocytes 
exposed to 4-HNE levels above 125 IJM. Cell membrane permeability (TOTO-3 flourescence) 
was increased in hepatocytes treated with 125 and 250 IJM 4-HNE. At 24 hours after 125 and 
250 IJM 4-HNE addition, there is significantly increased mitochondrial membrane potential 
(TMRM fluorescence) in hepatocytes pretreated with 1.52 IJM Alda-1 (Fig. 3) .. Additionally, cell 
membrane permeability (TOTO-3 fluorescence) was significantly decreased in hepatocytes 
pretreated with 1.52 IJM Alda-1 prior to 4-HNE exposure at 125 and 250 IJM. Representative 
photomicrographs (Fig. 4) of hepatocytes exposed to 250 IJM of 4-HNE are presented as well. 
Basal levels of mitochondrial membrane potential (red) and cell membrane permeability (green) 
are presented in the control photomicrograph. At 250 IJM 4-HNE, hepatocytes have low 
mitochondrial membrane potential but increased cell membrane permeability. Alda-1 (1.52 IJM) 
in the presence of 250 IJM 4-HNE was able to rescue mitochondrial membrane potential and 
blunt cell membrane permeability. 
Approximately 81% of cells pretreated with Alda-1 had normal mitochondrial membrane 
potential (>200 AU) and low plasma membrane permeability «200 AU). This is contrasted with 
41 % of cells exposed to 4-HNE meeting the same criteria (Fig. 5). 
Decreasing ALDH2 activity with Daidzin enhances hepatocyte death 
Daidzin is a known ALDH2 inhibitor that was employed to determine if we could block the 
protective effect of Alda_1. 35 Multiple concentrations of 4-HNE were tested and the 
predetermined concentration of Alda-1 (1.52 IJM) was coincubated with Daidzin (60 IJM) prior to 
the 4-HNE exposure. 
Mitochondrial membrane potential following 24 H incubation with 125 and 250 IJM 4-HNE 
in the presence of Alda-1 and Daidzin was significantly increased compared to controls on 
average. Interestingly, at a 250 IJM concentration of 4-HNE the protective effect of Alda-1 was 
significantly blunted in the presence of Daidzin (Fig. 3). Cell membrane permeability was 
significantly decreased compared to the control group at 125 and 250 IJM HNE incubations, 
however, the protection was significantly blunted when compared to hepatocytes pretreated with 
Alda-1 alone. 
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The individual hepatocyte data showed no difference between Alda-1 and the Daidzin 
plus Alda-1 groups alone (Fig. 5). However, in the presence of 250 IJM 4-HNE 81 % of 
hepatocytes had normal function in the Alda-1 group compared to 65% of hepatocytes in the 
Daidzin plus Alda-1 group. 
Administration of EtOH prior to hepatocyte isolation protected hepatocytes from 4-HNE 
toxicity 
Mice were pretreated with EtOH prior to hepatocyte isolation to further explore the 
enhanced regeneration observed by this treatment previously. Multiple concentrations of 4-HNE 
were tested following the acute EtOH pretreatment period. 
Mitochondrial membrane potential was decreased and cell membrane permeability was 
increased in control hepatocytes following 24 H exposure to 125 IJM 4-HNE (Figs. 6 and 7). 
Hepatocytes isolated from animals pretreated with EtOH were protected from the effects of 125 
IJM 4-HNE. Approximately 30% of hepatocytes from the control group were in a stage of cell 
dysfunction (i.e., <200 AU TMRM or >200 AU TOTO-3 flourescence) following 24 H incubation 
with 4-HNE while only 18% fit this criteria from the EtOH pretreatment group. 
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DISCUSSION 
The liver has tremendous ability to regenerate, however this regenerative ability is 
inhibited in fibrosis and cirrhosis. Our lab has shown that acute EtOH administration enhanced 
hepatic regeneration following PHx. These results led us to look more closely at ALDH2, which is 
key to the final step in EtOH oxidation. Lipid peroxides, which cause oxidative stress, are a 
product of PHx and are metabolized by ALDH2. Our results suggested that ALDH2 played an 
important role in mitigating the oxidative stress caused by PHx, thus protecting hepatocytes from 
further injury and enhancing the regenerative ability of the liver. 
To further explore this mechanism we employed Cellomics HCS which allowed us to look 
at several endpoints in isolated mouse hepatocytes (e.g. mitochondrial membrane potential and 
cell membrane integrity). The first goal was to show that by enhancing ALDH2 activity with 
Alda-1 we could protect hepatocytes from 4-HNE, a lipid peroxide. Next, we also wanted to show 
that addition of Daidzin (ALDH2 inactivator) could blunt the protective effect of Alda-1. Lastly, we 
wanted to see if the protection from acute EtOH could be replicated in the in vitro setting. 
A method for evaluating primary hepatocytes with the Cellomics HCS was adapted from 
techniques the lab already was familiar with (i.e. liver perfusion, hepatocyte isolation, and cell 
culture) and a paper by O'Brien et al which evaluated HepG2 cell toxicity with the Cellomics 
HCS.14 We found that setting up 10,000 cells/well on 96-well plates was able to provide a 
monolayer to be analyzed with the Cellomics HCS. Additionally, we determined that in primary 
hepatocytes Hoechst, TOTO-3, and TMRM fluorescent dyes could be analyzed but Flou-4 was 
not used due to high background from autofluorescence generated from the hepatocytes.36 
Lastly, we were able to determine appropriate concentrations of 4-HNE, Alda-1 and Daidzin to 
use in our experimental design. 
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The Cellomics HCS data here supported the initial hypothesis and showed a protective 
effect of Alda-1 when exposed to 4-HNE. At the well level as illustrated in Fig. 3, mitochondrial 
membrane potential was protected and cell membrane permeability was blunted when 
hepatocytes were pre-treated with Alda-1. These effects were also carried through to the 
individual cell data. These data help to illustrate the depth of analyses available with the 
Cellomics HCS. While the well data was able to show protection, the cell level data allows us to 
evaluate multiple parameters against one another. For example, we can see that the 
mitochondrial membrane potential begins to decrease before increase in cell membrane 
permeability (Figs. 5 and 6). This gives us insight into the mechanism behind cell death; which as 
expected was a result of mitochondrial injury from 4-HNE exposure.37 
Co-incubation of Alda-1 and Daidzin impaired the protective effect of Alda-1 when 
hepatocytes were exposed to 4-HNE. Daidzin did not completely ablate the Alda-1 effect but 
there was a Significant decrease in the mitochondrial membrane potential and increase in cell 
membrane permeability. This effect was seen not only at the well level but also at the individual 
cell level. The cell level data shows that again mitochondrial function was decreased prior to cell 
death. Because the binding site for Daidzin on ALDH2 overlaps the binding site for Alda-1, higher 
concentrations of Daidzin may lead to even further blunting of the Alda-1 protection. 
Finally, although not as strong an effect, we were able to show some protection of acute 
EtOH pretreatment from 4-HNE toxicity. Cell death was mediated first by a loss in mitochondrial 
function and then a loss in membrane integrity. This is further confirmation that by enhancing 
ALDH2 activity we can protect mitochondrial function and in turn protect cell viability. EtOH 
increases ALDH2 activity by going through the intermediate step of PKC£ activation, which in turn 
phosphorylates ALDH2, thereby increasing the activity of the enzyme.38.39 Others have shown 
that if PKC£ is not stimulated by sustained EtOH administration then the protection it affords is 
lost over time.40.41 This may account for the less dramatic protection of acute EtOH pre-treatment 
in the Cellomics HCS experiments. These results show that by increasing the activity of ALDH2, 
4-HNE toxicity can be blunted. 
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Although this research was performed in hepatocytes, ALDH2 is expressed at high levels 
in multiple tissues (i.e. brain, lung, and heart).42 Suggesting that the protective effect ALDH2 
activation provides from 4-HNE toxicity may also apply to these tissues. Indeed, the initial work 
with Alda-1 was performed in an ischemiaireperfusion model in rat hearts.32 This work showed 
that by enhancing ALDH2 activity, rat hearts were protected from the ischemic injury. 
Importantly, the protective effect was linked to increased 4-HNE metabolism by ALDH2. 
Recently, the same group showed that a topical application of Alda-1 reduced the severity and 
delayed the onset of dermatitis resulting from irradiation.43 Again in this model, 4-HNE adducts 
were significantly decreased in the skin of the mice. These data show the utility of ALDH2 
activation in multiple tissues and the protection afforded from increased 4-HNE metabolism. 
It is becoming clear that individuals with the ALDH2*2 polymorphism are more 
susceptible to various diseases.44 Indeed, a link has been established between the ALDH2*2 
polymorphism and increased risk for developing Alzheimer's Disease.45 The authors again 
suggest that the inability to metabolize 4-HNE may playa causal role in the development of 
Alzheimer's Disease. This suggests that the higher incidence of Alzheimer's Disease in 
individuals with the ALDH2*2 polymorphism may be prevented by increasing the activity of the 
mutant ALDH2. Recently, Shea and Remington argued that we are intervening too late in the 
development of Alzheimer's Disease.46 Perhaps increasing the activity of ALDH2 in populations 
susceptible to the disease, prior to the onset of the disease, will decrease the incidence rate. 
Taken together, these results show the possible utility in increasing the activity in ALDH2 
to protect against various diseases. The mechanisms all link metabolism of 4-HNE (resulting 
from oxidative stress) by ALDH2 to protecting against the progression of the respective malady 
(Fig. 8). While most of the work discussed above links the ALDH2*2 polymorphism with 
increased incidences of disease, there may be therapeutic utility for the increased activity in 
ALDH2 wild-type individuals. For example, the Alda-1 experiments discussed above used 
animals which had the wild type ALDH2 enzyme. A possible therapeutic effect was suggested in 
the skin irradiation experiment for individuals exposed to high levels of radiation. If a therapeutic 
effect of increased ALDH2 activity is confirmed then this could provide a therapy for several 
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maladies (e.g. ALD, Alzheimer's Disease, Myocardial Infarction). Thus, increasing ALDH2 
activity may prove a useful tool in prevention and/or treatment of various chronic disease states. 
Further experiments should be performed to verify the findings presented in this 
document. An ALDH2 knockout mouse has been developed and used previously in published 
reports.47.48 Hepatocytes from these knockout mice should be isolated and analyzed employing 
the methods designed here. From these follow up experiments we could determine if 4-HNE 
toxicity is increased in hepatocytes lacking ALDH2. Additionally, we could further confirm that 
Alda-1 protection is mediated through ALDH2 activation. Lastly, Daidzin inactivates ALDH2 and 
should therefore have no effect in ALDH2 knockout mice. The collection of these data would help 
to further strengthen the case that ALDH2 is key to enhancing hepatocyte viability. 
Second, in order to verify our hypothesis that ALDH2 activation by acute EtOH 
administration protects hepatocytes from 4-HNE toxicity we could again employ the ALDH2 
knockout mice. If our model is correct then no protection would be afforded to hepatocytes from 
these mice following acute EtOH treatment. Additionally, these mice could be used in the PHx 
model to evaluate liver regeneration following acute EtOH administration. At the present time no 
research has been done to characterize liver regeneration in ALDH2 knockout mice (PubMed 
search using the terms: ALDH2, knockout, liver and regeneration). By performing these 
experiments we could further understand the role of ALDH2 in protecting hepatocytes from 4-
HNE toxicity and determine what effect the lack of ALDH2 has on liver regeneration (in MD and 
EtOH pretreated mice). 
14 
SUMMARY AND CONCLUSIONS 
The final phase of ALD results in fibrosis and cirrhosis, which cause impaired hepatic 
regeneration. Currently there is no therapy to prevent or reverse the disease. Through further 
study of the disease and its mechanisms a viable therapy can be developed. To that end, the lab 
looked to evaluate the effects of acute EtOH on hepatic regeneration. It is well known that 
chronic EtOH administration impairs hepatic regeneration. The finding that acute EtOH enhanced 
hepatic regeneration was very interesting and found to be associated with an increase in ALDH2 
activity. 
Cellomics HCS has previously been used by O'Brien et al. to show high specificity and 
selectivity for toxic compounds in HepG2 cells. This showed that the Cellomics HCS was indeed 
a very powerful tool to understand hepatotoxicity in the liver. We in turn developed a method 
using primary hepatocytes in the Cellomics HCS that allowed us to assess mitochondrial function 
and cell membrane permeability in these cells. We then used the method to expose hepatocytes 
to 4-HNE while modulating ALDH2 activity. We found that increasing ALDH2 activity with either 
Alda-1 or acute EtOH pretreatment protected mitochondrial membrane potential and cell 
membrane integrity. Additionally by impairing ALDH2 with Daidzin we were able to blunt the 
protective effect of Alda-1 . 
At this time there is no therapy to enhance hepatic regeneration in ALD. These data 
suggest that by increasing ALDH2 activity we can decrease oxidative stress. By decreasing 
oxidative stress perhaps we can halt or even reverse the progression of ALD. ALDH2 activation 
has shown promise in protecting against other injuries that result in oxidative stress as well 
(ischemia/reperfusion and irradiation) which shows applications outside of ALD. Additionally, 
increasing ALDH2 activity may be a therapeutic target for other diseases (e.g. NAFLD and 
Alzheimer's Disease); indicating utility for the enzyme far beyond the scope of this research. 
15 
~E > CI) 
~ (5 12 o ... 
<c. 
N 01 10 
J: E 




'0 E 4 g c 
.r: - 2 
oJ: 
~ 5! 0 
::E~ MD EtOH 
c 
~ 




~ ~ 6 
O .l!! 
...J 0 4 
< E 




---- MO a a ---<>- EtOH 
~ 0 -'---'-':TO=-:"12=:"h"'"'2:-:-4:-h ~""h----:7==2Th -=96-::-:h~--' 
EtOH+Vehicle .. .. . ; 
0' 
Fig. 1: Summary of results from acute ethanol administration 
Male C57BLl6J mice were pretreated with maltose dextrin or ethanol for 3 days 
and PHx were performed on day 4 as described in Methods. ALDH2 and ALDHs 
activity were determined and PCNA immunohistochemical analysis was 
performed on tissue samples. Quantitative data are means ± SEM. a, p < 0.05 
compared to time = 0; b, p < 0.05 compared to MD control of the same time point 
after PHx. 
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Fig. 2: Experimental Design 
Hepatocytes were isolated on Day O. For experiments using Alda-1, the 
hepatocytes were exposed to Alda-1 (1.52 !-1M) for 30 min prior to addition of 
4-HNE (0-1 mM). For experiments with EtOH pre-exposure, animals were 
administered EtOH (6 g/kg Lg.) or MD for 3 days prior to hepatocyte isolation. 
The hepatocytes were exposed to 4-HNE (0-1 mM) from 0-24h. At 
corresponding time points, fluorescent dyes were added to the hepatocytes and 
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Fig. 3: Effect of modulated ALDH2 activity on average hepatocyte viability 
Mitochondrial membrane potential (TMRM fluorescence) and cell membrane 
permeability (TOTO-3) were determined using the Cellomics HCS. Hepatocyte 
viability data are means ± SEM (n = -200). a, p < 0.05 compared to control, b, p 
< 0.05 compared to Alda-1. 
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Fig. 4: Representative composite photomicrographs (20x) depicting 
individual cell analyses by Cellomics HCS 
Nuclear fluorescence (Hoechst; blue), mitochondrial membrane potential (TMRM; 
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Fig. 5: Effect of Alda-1 pre-treatment on individual hepatocyte viability. 
Cell membrane permeability (TOTO-3) as a function of mitochondrial membrane 
potential (TMRM) were determined using Cellomics HCS. 
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Fig. 6: Effect of EtOH pre-exposure on individual hepatocyte viability 
following 24h incubation with 4-HNE 
Individual Cell Data Analyses. Cell membrane permeability (TOTO-3) as a 











Fig. 7: Effect of EtOH pre-exposure on individual hepatocyte viability 
following 24h incubation with 4-HNE. 
Representative composite photomicrographs (20x) depicting analyses by 
Cellomics HCS. Nuclear fluorescence (Hoechst; blue), mitochondrial membrane 




ROS ___ , Lipid _!!--..... I 4-HNEL"--,",!""!~---!"",, 4-HNA 
peroxidation rrearve) non-reacfive) 
4-HNE adducts 
Fig. 8: Proposed mechanism of ALDH2 protection from oxidative injury 
Reactive oxygen species (ROS) induce lipid peroxidation which produces 4-HNE. 
ALDH-2 metabolizes 4-HNE to its non-reactive product 4-HNA. If ALDH2 is 
inactivated by high concentrations of 4-HNE then 4-HNE adducts can form and 
cause cell death. By pre-treating with EtOH or Alda-1 we can protect against 
4-HNE toxicity by increasing ALDH2 activity. 
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